Neha Vapiwala, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: September 27, 2005
Feb 2, 2011 - The number of fatal adverse events in cancer patients treated with the angiogenesis inhibitor bevacizumab in combination with chemotherapy or biological therapy is higher than those treated with chemotherapy alone, according to a review published in the Feb. 2 issue of the Journal of the American Medical Association.
Feb 2, 2011
Feb 27, 2015